Adam Maeder
Stock Analyst at Piper Sandler
(3.00)
# 1,194
Out of 5,182 analysts
106
Total ratings
42.31%
Success rate
1.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Maeder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NSPR InspireMD | Reiterates: Overweight | $4 → $3 | $1.16 | +158.62% | 5 | May 5, 2026 | |
| INSP Inspire Medical Systems | Downgrades: Neutral | $85 → $55 | $46.18 | +19.10% | 19 | May 5, 2026 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $620 → $580 | $454.30 | +27.67% | 23 | Apr 22, 2026 | |
| ABT Abbott Laboratories | Maintains: Overweight | $135 → $115 | $87.72 | +31.11% | 5 | Apr 17, 2026 | |
| RXST RxSight | Maintains: Neutral | $11 → $10 | $6.07 | +64.74% | 4 | Feb 26, 2026 | |
| TCMD Tactile Systems Technology | Maintains: Overweight | $35 → $42 | $26.40 | +59.09% | 6 | Feb 18, 2026 | |
| EW Edwards Lifesciences | Reiterates: Overweight | $98 → $100 | $83.50 | +19.76% | 19 | Feb 11, 2026 | |
| RMD ResMed | Maintains: Neutral | $270 → $275 | $208.19 | +32.09% | 5 | Jan 30, 2026 | |
| SGHT Sight Sciences | Upgrades: Overweight | $5 → $9 | $5.30 | +69.81% | 3 | Jan 5, 2026 | |
| NYXH Nyxoah | Reiterates: Overweight | $12 → $9 | $3.13 | +187.54% | 9 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $21 | $19.28 | +8.92% | 2 | May 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 → $8 | $1.76 | +355.84% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.92 | +161.10% | 2 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $99 | $70.94 | +39.55% | 3 | May 5, 2022 |
InspireMD
May 5, 2026
Reiterates: Overweight
Price Target: $4 → $3
Current: $1.16
Upside: +158.62%
Inspire Medical Systems
May 5, 2026
Downgrades: Neutral
Price Target: $85 → $55
Current: $46.18
Upside: +19.10%
Intuitive Surgical
Apr 22, 2026
Maintains: Overweight
Price Target: $620 → $580
Current: $454.30
Upside: +27.67%
Abbott Laboratories
Apr 17, 2026
Maintains: Overweight
Price Target: $135 → $115
Current: $87.72
Upside: +31.11%
RxSight
Feb 26, 2026
Maintains: Neutral
Price Target: $11 → $10
Current: $6.07
Upside: +64.74%
Tactile Systems Technology
Feb 18, 2026
Maintains: Overweight
Price Target: $35 → $42
Current: $26.40
Upside: +59.09%
Edwards Lifesciences
Feb 11, 2026
Reiterates: Overweight
Price Target: $98 → $100
Current: $83.50
Upside: +19.76%
ResMed
Jan 30, 2026
Maintains: Neutral
Price Target: $270 → $275
Current: $208.19
Upside: +32.09%
Sight Sciences
Jan 5, 2026
Upgrades: Overweight
Price Target: $5 → $9
Current: $5.30
Upside: +69.81%
Nyxoah
Nov 14, 2025
Reiterates: Overweight
Price Target: $12 → $9
Current: $3.13
Upside: +187.54%
May 22, 2024
Maintains: Hold
Price Target: $20 → $21
Current: $19.28
Upside: +8.92%
Mar 6, 2024
Reiterates: Overweight
Price Target: $7 → $8
Current: $1.76
Upside: +355.84%
Mar 6, 2023
Maintains: Overweight
Price Target: $6 → $5
Current: $1.92
Upside: +161.10%
May 5, 2022
Maintains: Overweight
Price Target: $104 → $99
Current: $70.94
Upside: +39.55%